Business Context and Reporting Period
Company: On Assignment, Inc. (Note: Input metadata referenced "Everforth Inc," but the filing text identifies the registrant as On Assignment, Inc.)
Filing Type: Form 10-Q
Reporting Period: Quarter and six months ended June 30, 2001
Business Overview: The Company operates two reportable segments: Lab Support (laboratory and scientific professionals) and Healthcare Staffing (medical billing and clinical staffing). It provides temporary and permanent placement services.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2001 | Six Months Ended June 30, 2000 | Three Months Ended June 30, 2001 | Three Months Ended June 30, 2000 |
|---|---|---|---|---|
| Revenues | $100,855,000 | $92,162,000 | $49,674,000 | $47,817,000 |
| Gross Profit | $32,791,000 | $30,100,000 | $16,065,000 | $15,654,000 |
| Gross Margin | 32.5% | 32.7% | 32.3% | 32.7% |
| Operating Income | $13,259,000 | $12,875,000 | $6,452,000 | $6,619,000 |
| Net Income | $9,329,000 | $8,730,000 | $4,503,000 | $4,524,000 |
| Diluted EPS | $0.40 | $0.38 | $0.19 | $0.20 |
| Cash from Operations | $15,597,000 | $10,785,000 | N/A | N/A |
| Cash & Equivalents (End of Period) | $68,722,000 | $37,919,000 | $68,722,000 | $37,919,000 |
| Total Assets | $122,241,000 | $105,556,000 | $122,241,000 | $105,556,000 |
| Total Current Liabilities | $12,979,000 | $10,265,000 | $12,979,000 | $10,265,000 |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 9.4% for the six months ended June 30, 2001, compared to the prior year. This was driven by a 9.4% increase in the Lab Support segment and a 9.5% increase in the Healthcare Staffing segment.
- Volume vs. Rates:
- Lab Support: Growth was primarily due to a 4.1% increase in the number of temporary employees on assignment and a 5.6% increase in average hourly billing rates.
- Healthcare Staffing: Growth was driven by a 5.8% increase in temporary employee volume and a 5.1% increase in billing rates.
- Cost Structure: Cost of services increased 9.7% year-over-year. Gross margins remained relatively stable but saw slight compression in both segments due to higher employer-paid benefits and workers' compensation premiums.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses increased 13.4% for the six-month period, rising from 18.7% to 19.4% of revenues. This was attributed to hiring new Account Managers for new and expanding offices.
- Interest Income: Interest income surged 47.4% for the six-month period, driven by higher balances in interest-bearing cash and marketable securities.
Guidance, Outlook, and Risks
- Management Commentary: Management attributes revenue growth to strong performance in established markets and contributions from new offices. They note that one fewer working day in the 2001 period partially offset revenue gains.
- Liquidity: The Company reported a net increase in cash of $17.5 million for the six-month period. Management believes current cash balances, operating funds, and borrowing ability are sufficient to meet requirements for the next twelve months.
- Capital Allocation: The Company repurchased $754,000 of common stock during the period. As of June 30, 2001, 2,238,500 shares remained available for repurchase under the Board's authorization.
- Executive Transition: The Board completed a search for a new CEO to succeed H. Tom Buelter. Joe Peterson, M.D., was announced to join as CEO in July 2001.
- Risks: Key risks include the ability to attract and retain qualified staff, management of growth in international markets, and integration of acquired operations. The Company is also evaluating the impact of new accounting standards (SFAS 141 and 142) regarding goodwill, effective in fiscal 2002.
Investor Verification Checklist
- Executive Transition: Verify the start date and initial strategic plans of the new CEO, Joe Peterson, M.D.
- Margin Pressure: Monitor the trend of workers' compensation premiums and benefit costs, which are compressing gross margins despite revenue growth.
- SG&A Efficiency: Assess whether the 19.4% SG&A-to-revenue ratio stabilizes as new offices mature and leverage the centralized support system.
- Accounting Changes: Review the impact of the upcoming adoption of SFAS 142 (Goodwill and Other Intangible Assets) on future earnings, as the Company will stop amortizing goodwill and instead test for impairment.
- Cash Utilization: Track the deployment of the $68.7 million cash balance, specifically regarding continued stock repurchases versus potential acquisitions or dividends.